Mohan Vishudh, Patro Sourabha Kumar, Purohit Purvi, Sharma Vidhu, Soni Kapil, Choudhury Bikram, Goyal Amit
Department of Otorhinolaryngology, All India Institute of Medical Sciences Jodhpur, Jodhpur, Rajasthan 342005 India.
Department of Otorhinolaryngology and Head and Neck Surgery, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Indian J Otolaryngol Head Neck Surg. 2025 Jan;77(1):149-154. doi: 10.1007/s12070-024-05129-1. Epub 2024 Oct 12.
Human defensins are peptides coded by certain genes released as a part of immune response that act differently to tumorigenic cells according to the class. A varied cellular response has been documented in the world literature concerning the role of defensins in the cancer cell lines, though the exact role in the internal human milieu and the role specific to head and neck cancers is still understudied. This study explores the possible role of Human Beta Defensin (HBD) 1 and 3 in head and neck squamous cell carcinoma in disease progression and their potential as biomarkers/prognostic markers. Two samples, one from the cancerous tissue and one from the normal tissue margin were taken and sent for molecular analysis, viz. mRNA isolation and PCR. The fold change gene expression of HBD 1 and 3 was calculated using a housekeeping gene, and then, as per the available results, we tried to objectify the relative expression of HBD 3 and HBD 1 and its ratio. Out of the 40 samples, 26 were adequate and processed. Expression of HBD1 (DEFB1) and HBD3 (DEFB-103 A) was assessed. Normal tissues were taken as control. GADPH (Glyceraldehyde-3-Phosphate dehydrogenase) was used as an internal control. The cycle of quantification (cq) was calculated for the cases and control. A more than two-fold (2.85 times) increase in expression of HBD1 was found; however, no expression of HBD3 was shown in both cancer tissue and control tissue samples. Additional investigations with a larger sample size, encompassing the expression analysis of cancer genes at various clinico-histopathological stages, are imperative before designating them as biomarkers.
人类防御素是由某些基因编码的肽，作为免疫反应的一部分释放出来，根据类别对致瘤细胞有不同作用。关于防御素在癌细胞系中的作用，世界文献中已记录了多种细胞反应，不过其在人体内部环境中的确切作用以及对头颈部癌症的特异性作用仍研究不足。本研究探讨了人类β防御素（HBD）1和3在头颈部鳞状细胞癌疾病进展中的可能作用及其作为生物标志物/预后标志物的潜力。采集了两个样本，一个来自癌组织，一个来自正常组织边缘，送去进行分子分析，即mRNA分离和PCR。使用管家基因计算HBD 1和3的基因表达倍数变化，然后根据现有结果，我们试图确定HBD 3和HBD 1的相对表达及其比例。40个样本中，26个样本足够并进行了处理。评估了HBD1（DEFB1）和HBD3（DEFB - 103 A）的表达。以正常组织作为对照。使用甘油醛 - 3 - 磷酸脱氢酶（GADPH）作为内对照。计算了病例组和对照组的定量循环（cq）。发现HBD1的表达增加了两倍多（2.85倍）；然而，癌组织和对照组织样本中均未显示HBD3的表达。在将它们指定为生物标志物之前，必须进行更大样本量的进一步研究，包括在各种临床组织病理学阶段对癌症基因的表达分析。
